$15.680
+3.528 (+22.50%)At close
- High
- 18.600
- Open
- 12.080
- VWAP
- 15.16
- Vol
- 3.44M
- Mkt Cap
- 4.64M
- Low
- 11.200
- Amount
- 52.08M
- EV/EBITDA, TTM
- 0.00
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Analyst Ratings (1)
Alliance Global Partners
$233
2022-05-26
Alliance Global Partners
2022-05-26
Price Target
$233
Maxim Group
—
2021-10-08
Maxim Group
2021-10-08
Price Target
—
Valuation Metrics
Events Timeline
News
8.508-14NewsfilterVyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
2.008-14TipRanks3 Penny Stocks to Watch Now, 8/14/25
- 8.508-13Newsfilter
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
5.008-12NewsfilterVyome Announces New Board of Directors with Deep MIT and AI Ties
1.007-24NewsfilterReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
RSLS FAQ — answered by Alphio AI
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
1 analysts cover RSLS: 1 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.